BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45:960-967. [PMID: 20376504 DOI: 10.1007/s00535-010-0237-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 109] [Article Influence: 8.4] [Reference Citation Analysis]
2 Bellentani S, Scaglioni F, Ciccia S, Bedogni G, Tiribelli C. HCV, HBV and Alcohol – the Dionysos Study. Dig Dis 2010;28:799-801. [DOI: 10.1159/000324288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N, Miyakawa Y, Nishino H, Tajiri H. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol. 2012;29:2800-2808. [PMID: 22460836 DOI: 10.1007/s12032-012-0220-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
4 Skill NJ, Butler J, O’brien DC, Kays JK, Kubal CA, Liangpunsakul S, Ninad N, Maluccio MA. Financial Burden of Liver Transplant vs Resection for Hepatocellular Carcinoma. Transplantation Proceedings 2019;51:1907-12. [DOI: 10.1016/j.transproceed.2019.04.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K, Eguchi Y, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Suzuki Y, Kogiso T, Karino Y, Munekage K, Kuromatsu R, Oeda S, Yanase M, Mori K, Ogawa Y, Seko Y, Takehara T, Itoh Y, Nakajima A, Kanemasa K, Nishino K, Masaki N, Takahashi H, Seike M, Torimura T, Saibara T, Toyota J, Chayama K, Hashimoto E. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. J Gastroenterol 2016;51:586-96. [PMID: 26456168 DOI: 10.1007/s00535-015-1129-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
6 Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Survival after surgery for hepatocellular carcinoma in relation to presence or absence of viral infection. The American Journal of Surgery 2013;206:187-93. [DOI: 10.1016/j.amjsurg.2012.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 61] [Article Influence: 17.4] [Reference Citation Analysis]
8 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Reference Citation Analysis]
9 Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Tsai YJ, Nagaria TS, Lin HC, Huo TI. Active Treatments Prolong the Survival in Patients With Hepatocellular Carcinoma and Performance Status 3 or 4: A Propensity Score Analysis. J Clin Gastroenterol 2015;49:878-84. [PMID: 25710525 DOI: 10.1097/MCG.0000000000000300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Hsu CY, Lee YH, Liu PH, Hsia CY, Huang YH, Lin HC, Chiou YY, Lee FY, Huo TI. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model. PLoS One 2014;9:e89373. [PMID: 24586728 DOI: 10.1371/journal.pone.0089373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
11 Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28 Suppl 4:64-70. [PMID: 24251707 DOI: 10.1111/jgh.12271] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 14.6] [Reference Citation Analysis]
12 Tokushige K, Hashimoto E, Kodama K. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan. J Gastroenterol Hepatol. 2013;28 Suppl 4:88-92. [PMID: 24251711 DOI: 10.1111/jgh.12239] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
13 Shrager B, Jibara GA, Tabrizian P, Roayaie S, Ward SC. Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience. Int J Surg Oncol. 2012;2012:915128. [PMID: 22988496 DOI: 10.1155/2012/915128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
14 Chin KM, Prieto M, Cheong CK, Di Martino M, Ielpo B, Goh BKP, Koh YX. Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature. HPB (Oxford) 2021;23:1164-74. [PMID: 33608215 DOI: 10.1016/j.hpb.2021.01.009] [Reference Citation Analysis]
15 Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, Min BY, Jang ES, Kim JW, Park GJ. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer. 2013;13:335. [PMID: 23829392 DOI: 10.1186/1471-2407-13-335] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
16 Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Chiou YY, Lin HC, Huo TI. Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. Medicine (Baltimore) 2015;94:e1223. [PMID: 26200647 DOI: 10.1097/MD.0000000000001223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 256] [Article Influence: 69.7] [Reference Citation Analysis]
18 Matsuda Y, Wakai T, Hirose Y, Osawa M, Fujimaki S, Kubota M. p27 Is a critical prognostic biomarker in non-alcoholic steatohepatitis-related hepatocellular carcinoma. Int J Mol Sci 2013;14:23499-515. [PMID: 24351862 DOI: 10.3390/ijms141223499] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
19 Reddy SK, Steel JL, Chen H, Demateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA, Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19. [DOI: 10.1002/hep.25536] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 12.4] [Reference Citation Analysis]
20 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
21 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012;42:1-14. [PMID: 21917086 DOI: 10.1111/j.1872-034x.2011.00872.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
22 Duan XY, Zhang L, Fan JG, Qiao L. NAFLD leads to liver cancer: do we have sufficient evidence? Cancer Lett 2014;345:230-4. [PMID: 23941829 DOI: 10.1016/j.canlet.2013.07.033] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
23 Kwak M, Kim D. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2015;14:69-76. [DOI: 10.1007/s11901-015-0258-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
24 Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17:748-755. [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
25 Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015;19:361-79. [PMID: 25921668 DOI: 10.1016/j.cld.2015.01.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 13.4] [Reference Citation Analysis]
26 Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011;15:281-96, vii-x. [PMID: 21689613 DOI: 10.1016/j.cld.2011.03.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
27 Izumi N. Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma. Hepatol Res. 2012;42:226-232. [PMID: 22181559 DOI: 10.1111/j.1872-034x.2011.00922.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
28 Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46:1230-1237. [PMID: 21748549 DOI: 10.1007/s00535-011-0431-9] [Cited by in Crossref: 91] [Cited by in F6Publishing: 75] [Article Influence: 8.3] [Reference Citation Analysis]
29 Tobari M, Hashimoto E, Taniai M, Nishino T, Tokushige K. Hepatocellular carcinoma in young morbid obese patients with non-alcoholic fatty liver disease. Clin J Gastroenterol 2020;13:1289-96. [PMID: 32880022 DOI: 10.1007/s12328-020-01215-3] [Reference Citation Analysis]
30 Patwardhan V, Paul S, Corey KE, Mazhar SM, Richter JM, Thiim M, Chung RT. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011;56:3316-3322. [PMID: 21805170 DOI: 10.1007/s10620-011-1836-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
31 Hsu C, Liu P, Lee Y, Hsia C, Huang Y, Chiou Y, Tsai Y, Nagaria TS, Huo T. Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. Ann Surg Oncol 2015;22:1324-31. [DOI: 10.1245/s10434-014-4151-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
32 Peluso MEM, Munnia A, Tarocchi M, Arciello M, Balsano C, Giese RW, Galli A. Exocycilic DNA Adducts in a Murine Model of Non-alcoholic Steatohepatitis. J Carcinog Mutagen 2013;2013:003. [PMID: 31528500 DOI: 10.4172/2157-2518.S3-003] [Reference Citation Analysis]
33 Berkan-Kawińska A, Piekarska A. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Curr Med Res Opin 2020;36:235-43. [PMID: 31631714 DOI: 10.1080/03007995.2019.1683817] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
34 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Vongsuvanh R, van der Poorten D, George J. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. Hepatol Int 2013;7 Suppl 2:823-32. [PMID: 26202297 DOI: 10.1007/s12072-013-9453-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
36 Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33:86-98. [PMID: 28692197 DOI: 10.1111/jgh.13856] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 18.3] [Reference Citation Analysis]
37 Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2012;11:18-27. [PMID: 22251466 DOI: 10.1016/s1499-3872(11)60120-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
38 Kawai H, Nomoto M, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Yano M, Takamura M, Igarashi M, Wakai T, Yamagiwa S, Matsuda Y, Ohkoshi S, Kurosaki I, Shirai Y, Okada M, Aoyagi Y. Multicentric occurrence of hepatocellular carcinoma with nonalcoholic steatohepatitis. World J Hepatol 2011; 3(1): 15-23 [PMID: 21307983 DOI: 10.4254/wjh.v3.i1.15] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
39 Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81. [PMID: 27634970 DOI: 10.1093/qjmed/hcw151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
40 Singh S, Kuftinec GN, Sarkar S. Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature. J Clin Transl Hepatol. 2017;5:76-81. [PMID: 28507930 DOI: 10.14218/jcth.2016.00045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
41 Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, Hatakeyama K. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. J Gastrointest Surg. 2011;15:1450-1458. [PMID: 21512848 DOI: 10.1007/s11605-011-1540-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
42 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.001] [Cited by in Crossref: 413] [Cited by in F6Publishing: 392] [Article Influence: 41.3] [Reference Citation Analysis]
44 Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00505-X. [PMID: 33965578 DOI: 10.1016/j.cgh.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 2019;149:9-17. [PMID: 31115369 DOI: 10.4103/ijmr.ijmr_1456_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
46 Matsumura H, Nirei K, Nakamura H, Higuchi T, Arakawa Y, Ogawa M, Tanaka N, Moriyama M. Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors. World J Gastroenterol 2013; 19(30): 4887-4896 [PMID: 23946593 DOI: 10.3748/wjg.v19.i30.4887] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
47 Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011;46:63-9. [DOI: 10.1007/s00535-010-0311-8] [Cited by in Crossref: 152] [Cited by in F6Publishing: 137] [Article Influence: 12.7] [Reference Citation Analysis]